Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

LY 4052031

Next Previous
X
Search
Drug Profile

LY 4052031

Alternative Names: LY-4052031

Latest Information Update: 05 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cancer; Solid tumours

Most Recent Events

  • 01 Jul 2024 Phase-I clinical trials in Solid tumours (Metastatic disease, Late-stage disease, Second-line therapy or greater) in USA (IV) (NCT06465069) (EudraCT2024-512927-36-00)
  • 21 Jun 2024 Eli Lilly and Company plans phase I NEXUS-01 trial in Solid tumours (Metastatic disease, Late-stage disease and Second-line therapy and greater) in US in June 2024 (IV) (NCT06465069)
  • 27 May 2024 Phase-I clinical trials in Cancer (Parenteral) prior to May 2024 (Eli Lilly and Company Pipeline, May 2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top